About the Startup
UK biotechnology spin-out developing targeted AAV gene therapies for focal refractory epilepsy; lead program EPY201 is delivered locally to seizure foci to reduce overactive neurons and aims to advance into Phase 1/2a clinical trials.
Frequently Asked Questions
What type of funding round did EpilepsyGTx raise?
EpilepsyGTx raised a series-a round.
How much did EpilepsyGTx raise in its series-a?
EpilepsyGTx raised $33,000,000 USD in its series-a.
When did EpilepsyGTx raise its series-a?
EpilepsyGTx raised its series-a on 2025-12-11.
Who invested in EpilepsyGTx's series-a?
The investors in EpilepsyGTx's series-a are: XGEN Venture, British Business Bank, Global biopharmaceutical company.
What type of investment was EpilepsyGTx's series-a?
EpilepsyGTx's series-a was a equity investment.